Securities code: 300463 securities abbreviation: Maccura Biotechnology Co.Ltd(300463) Announcement No.: 2022-007
Maccura Biotechnology Co.Ltd(300463)
Announcement on obtaining product registration certificate for new products of the company
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions.
Maccura Biotechnology Co.Ltd(300463) (hereinafter referred to as “the company”) recently received the medical device registration certificate issued by the State Drug Administration. The details are as follows: I. details of the product registration certificate
Sequential registration
Product name registration certificate number registration certificate validity intended use
Number category
Hepatitis C virus 1 Detection Kit (colloid III) for in vitro qualitative detection of hepatitis C virus antibody in human serum or blood from December 31, 2021 to December 31, 2021
Gold method) 20213401120 December 30, 2026 (hepatitis C virus, HCV) antibody.
2、 Impact on the company
Hepatitis C virus antibody detection kit (colloidal gold method) is a new product of the company’s rapid detection (POCT) product platform. The registration certificate of the product will help to improve the company’s comprehensive market competitiveness and will have a positive impact on the market expansion and future operation of the company. 3、 Risk tips
The actual sales of the products involved in the above registration certificate depends on the future marketing effect. At present, it is impossible to predict the impact of the product on the company’s future operating revenue. Please pay attention to the investment risk.
It is hereby announced.
Maccura Biotechnology Co.Ltd(300463) securities code: 300463 securities abbreviation: Maccura Biotechnology Co.Ltd(300463) Announcement No.: 2022-007
Board of directors January 18, 2002
